Adeno-associated virus (AAV) vectored products are currently leading candidates for gene therapy applications with multiple approved products and many more in clinical trials.
Researchers at Stanford have developed methods to overcome the limited packaging capacity of adeno-associated virus (AAV) vectors and enable their use in integration of large transgenes.
Researchers in Dr. Mark Kay's laboratory at Stanford University have designed a new liver-specific expression cassette for inserting genes into double-stranded AAV (adeno-associated virus) vectors for gene therapy.